December 4, 2018
A key health ministry panel on December 3 gave the blessing to Amgen Astellas Biopharma’s osteoporosis treatment romosozumab after two years in limbo, while shelving a decision on Shionogi’s ADHD medicine lisdexamfetamine dimesylate, which has been designated as a stimulant...read more